Travere Q2 FY26 net loss widens to $34.8 million; FILSPARI net sales rise 96% year-over-year to $141.1 million - TVTX News | RalliesTravere Q2 FY26 net loss widens to $34.8 million; FILSPARI net sales rise 96% year-over-year to $141.1 million
T
TVTX• Travere reports wider quarterly loss as sales rise
- Travere posted Q2 GAAP net loss of USD 34.8 million, or USD 0.37 per share, versus a loss of USD 12.8 million a year earlier.
- Net sales rose 70.15% year over year to USD 161.4 million, driven by FILSPARI net sales up 96% to USD 141.1 million.
- R&D expense increased 22.06% to USD 60.3 million; SG&A climbed 53.54% to USD 96.1 million.
- Other expense widened to USD 39 million on a USD 40 million inducement expense tied to 2029 convertible note repurchases.
- The company received 2,012 new patient start forms in the quarter.
- Travere also closed civorebrutinib in-licensing in July, and pegtibatinase Phase 3 HARMONY topline data is expected in 2H 2027.
